Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate

C. L. Amling, B. C. Leibovich, S. E. Lerner, E. J. Bergstralh, M. L. Blute, R. P. Myers, H. Zincke

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Radical prostatectomy has not been a widely accepted treatment option in patients with clinical stage T3 prostate cancer due to the potential for incomplete excision of tumor and the high incidence of lymph node metastases. In addition, the morbidity of surgical therapy in these patients has been questioned. As a result, alternative treatment modalities, including androgen ablative therapy and radiotherapy, are often used in patients with locally advanced disease. However, in terms of local disease control and long-term disease-free survival rates, most alternative treatments have serious limitations in clinical stage T3 tumors. We recently reported our extended experience with radical prostatectomy and adjuvant therapy in a large group of patients with clinical stage T3 disease and this article updates that experience. Although 31% of patients in our series had node-positive disease, 25% had pathologically organ-confined tumors likely to be cured by surgical therapy alone. Cancer-specific survival rates at 5, 10, and 15 years were 93%, 84%, and 74%, respectively, and operative morbidity paralleled that of patients with clinically localized disease. Our experience suggests that excellent long-term survival with low treatment-related morbidity can be achieved with radical prostatectomy and adjuvant therapy in patients with clinical stage T3 prostate cancer.

Original languageEnglish (US)
Pages (from-to)215-221
Number of pages7
JournalSeminars in Urologic Oncology
Volume15
Issue number4
StatePublished - 1997

Fingerprint

Prostate
Adenocarcinoma
Prostatectomy
Therapeutics
Morbidity
Neoplasms
Prostatic Neoplasms
Survival Rate
Androgens
Disease-Free Survival
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Survival
Incidence

Keywords

  • Prostate
  • Prostatectomy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Amling, C. L., Leibovich, B. C., Lerner, S. E., Bergstralh, E. J., Blute, M. L., Myers, R. P., & Zincke, H. (1997). Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Seminars in Urologic Oncology, 15(4), 215-221.

Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. / Amling, C. L.; Leibovich, B. C.; Lerner, S. E.; Bergstralh, E. J.; Blute, M. L.; Myers, R. P.; Zincke, H.

In: Seminars in Urologic Oncology, Vol. 15, No. 4, 1997, p. 215-221.

Research output: Contribution to journalReview article

Amling, CL, Leibovich, BC, Lerner, SE, Bergstralh, EJ, Blute, ML, Myers, RP & Zincke, H 1997, 'Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate', Seminars in Urologic Oncology, vol. 15, no. 4, pp. 215-221.
Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, Myers RP et al. Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. Seminars in Urologic Oncology. 1997;15(4):215-221.
Amling, C. L. ; Leibovich, B. C. ; Lerner, S. E. ; Bergstralh, E. J. ; Blute, M. L. ; Myers, R. P. ; Zincke, H. / Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate. In: Seminars in Urologic Oncology. 1997 ; Vol. 15, No. 4. pp. 215-221.
@article{663c1f777c2e4a1fb344d13126acb60f,
title = "Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate",
abstract = "Radical prostatectomy has not been a widely accepted treatment option in patients with clinical stage T3 prostate cancer due to the potential for incomplete excision of tumor and the high incidence of lymph node metastases. In addition, the morbidity of surgical therapy in these patients has been questioned. As a result, alternative treatment modalities, including androgen ablative therapy and radiotherapy, are often used in patients with locally advanced disease. However, in terms of local disease control and long-term disease-free survival rates, most alternative treatments have serious limitations in clinical stage T3 tumors. We recently reported our extended experience with radical prostatectomy and adjuvant therapy in a large group of patients with clinical stage T3 disease and this article updates that experience. Although 31{\%} of patients in our series had node-positive disease, 25{\%} had pathologically organ-confined tumors likely to be cured by surgical therapy alone. Cancer-specific survival rates at 5, 10, and 15 years were 93{\%}, 84{\%}, and 74{\%}, respectively, and operative morbidity paralleled that of patients with clinically localized disease. Our experience suggests that excellent long-term survival with low treatment-related morbidity can be achieved with radical prostatectomy and adjuvant therapy in patients with clinical stage T3 prostate cancer.",
keywords = "Prostate, Prostatectomy, Prostatic neoplasms",
author = "Amling, {C. L.} and Leibovich, {B. C.} and Lerner, {S. E.} and Bergstralh, {E. J.} and Blute, {M. L.} and Myers, {R. P.} and H. Zincke",
year = "1997",
language = "English (US)",
volume = "15",
pages = "215--221",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Primary surgical therapy for clinical stage T3 adenocarcinoma of the prostate

AU - Amling, C. L.

AU - Leibovich, B. C.

AU - Lerner, S. E.

AU - Bergstralh, E. J.

AU - Blute, M. L.

AU - Myers, R. P.

AU - Zincke, H.

PY - 1997

Y1 - 1997

N2 - Radical prostatectomy has not been a widely accepted treatment option in patients with clinical stage T3 prostate cancer due to the potential for incomplete excision of tumor and the high incidence of lymph node metastases. In addition, the morbidity of surgical therapy in these patients has been questioned. As a result, alternative treatment modalities, including androgen ablative therapy and radiotherapy, are often used in patients with locally advanced disease. However, in terms of local disease control and long-term disease-free survival rates, most alternative treatments have serious limitations in clinical stage T3 tumors. We recently reported our extended experience with radical prostatectomy and adjuvant therapy in a large group of patients with clinical stage T3 disease and this article updates that experience. Although 31% of patients in our series had node-positive disease, 25% had pathologically organ-confined tumors likely to be cured by surgical therapy alone. Cancer-specific survival rates at 5, 10, and 15 years were 93%, 84%, and 74%, respectively, and operative morbidity paralleled that of patients with clinically localized disease. Our experience suggests that excellent long-term survival with low treatment-related morbidity can be achieved with radical prostatectomy and adjuvant therapy in patients with clinical stage T3 prostate cancer.

AB - Radical prostatectomy has not been a widely accepted treatment option in patients with clinical stage T3 prostate cancer due to the potential for incomplete excision of tumor and the high incidence of lymph node metastases. In addition, the morbidity of surgical therapy in these patients has been questioned. As a result, alternative treatment modalities, including androgen ablative therapy and radiotherapy, are often used in patients with locally advanced disease. However, in terms of local disease control and long-term disease-free survival rates, most alternative treatments have serious limitations in clinical stage T3 tumors. We recently reported our extended experience with radical prostatectomy and adjuvant therapy in a large group of patients with clinical stage T3 disease and this article updates that experience. Although 31% of patients in our series had node-positive disease, 25% had pathologically organ-confined tumors likely to be cured by surgical therapy alone. Cancer-specific survival rates at 5, 10, and 15 years were 93%, 84%, and 74%, respectively, and operative morbidity paralleled that of patients with clinically localized disease. Our experience suggests that excellent long-term survival with low treatment-related morbidity can be achieved with radical prostatectomy and adjuvant therapy in patients with clinical stage T3 prostate cancer.

KW - Prostate

KW - Prostatectomy

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0030692038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030692038&partnerID=8YFLogxK

M3 - Review article

C2 - 9421448

AN - SCOPUS:0030692038

VL - 15

SP - 215

EP - 221

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 4

ER -